Market Overview:
The global recombinant human interleukin 2 injection market is expected to register a CAGR of 7.5% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of cancer and other chronic diseases, rising demand for biologics and growing investments in R&D by key players. Based on type, the recombinant human interleukin 2 injection market is segmented into 50000 U, 100000 U, 200000 U, 500000 U and 1 million units. Among these segments, the 50000 unit segment is expected to account for a major share of the global market during the forecast period. This can be attributed to its low cost and easy availability as compared to other types of recombinant human interleukin 2 injections. Based on application, hospital accounted for a major share of the global recombinant human interleukin 2 injection market in 2017. This can be attributed to increasing number of cancer patients seeking treatment in hospitals across regions worldwide.
Product Definition:
A recombinant human interleukin-2 injection is a drug that is used to treat cancer. It helps the body's natural defenses fight cancer cells.
50000 U:
50000 U is the concentration of a human interleukin 2 (IL-2) unit. It is used as an injection for treatment of various cancers such as lymphomas, leukemias, and myelomas. The recombinant form of IL-2 has been approved by the FDA for treatment of patients with advanced melanoma in combination with chemotherapy and radiation therapy.
100000 U:
100000 U is a measure for the amount of protein used in recombinant human interleukin 2 (rhuil-2) injection. It is an unit that represents one microgram of human cytokine, which is used to measure the activity of rhuil-2 in a sample. The measurement can be performed by any method that provides for accurate and precise quantification of rhuil-2 using its standard curve.
Application Insights:
On the basis of application, the global recombinant human interleukin 2 injection market is segmented into hospital and pharmacy. The hospital segment dominated the overall market in terms of revenue in 2017 due to a high usage rate of recombinant human interleukin 2 for treatment purposes. Hospital-based settings are preferred by patients who require long-term therapy as they have a higher availability than other settings.
The pharmacist¢â‚¬â„¢s role is to ensure that every patient has access to safe and effective drugs while reducing health care costs through appropriate use of pharmaceutical products. This concept holds true for interleukin 2 as well; therefore, increasing demand from pharmacies may be attributed to growth over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers and distributors coupled with high healthcare expenditure, favorable reimbursement policies for rHIILs, and increasing incidence of cancer are some factors responsible for its continued dominance over the forecast period.
Asia Pacific is expected to be the fastest-growing region during the forecast period owing to an increase in awareness about rHIILs among patients, improving healthcare infrastructure especially in developing countries such as China & India, growing investment by private players along with government support towards research activities related to oncology diseases are few other factors driving growth. Moreover Interleukin 2 is a generic drug which has low price compared to branded ones; this will drive demand further due interleukin 2 being a generic drug having unmet medical needs it will have high demand from emerging markets such as Asia Pacific & Latin America thus making it one of largest revenue generators globally during the same period.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the recombinant human interleukin 2 injection market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This growing prevalence of cancer is expected to drive demand for recombinant human interleukin 2 injection products over the forecast period.
- Rising awareness about immunotherapy: The rising awareness about immunotherapy as a treatment option for various types of cancers is another major factor driving growth in the recombinant human interleukin 2 injection market. Immunotherapy involves using substances that stimulate or restore immune system function to fight diseases such as cancer and has been shown to be more effective than traditional chemotherapy treatments in some cases. As a result, there is an increasing demand for recombinant human interleukin 2 injections as part of immunotherapy regimens which is expected to propel market growth over the forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Recombinant Human Interleukin 2 Injection Market Research Report
By Type
50000 U, 100000 U, 200000 U, 500000 U, 1 Million U, Other
By Application
Hospital, Pharmacy
By Companies
Jiangsu Jinsili Pharmaceutical, 3SBio, Beijing SL Pharm, Shanghai Huaxin Biology Gaojishu, Beijing Four Rings Biopharmaceutical, Beijing Yuance Pharmaceutical, Shandong Quangang Pharmaceutical, Jiangsu Jinsili Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
127
Number of Tables & Figures
89
Customization Available
Yes, the report can be customized as per your need.
Global Recombinant Human Interleukin 2 Injection Market Report Segments:
The global Recombinant Human Interleukin 2 Injection market is segmented on the basis of:
Types
50000 U, 100000 U, 200000 U, 500000 U, 1 Million U, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Jiangsu Jinsili Pharmaceutical
- 3SBio
- Beijing SL Pharm
- Shanghai Huaxin Biology Gaojishu
- Beijing Four Rings Biopharmaceutical
- Beijing Yuance Pharmaceutical
- Shandong Quangang Pharmaceutical
- Jiangsu Jinsili Pharmaceutical
Highlights of The Recombinant Human Interleukin 2 Injection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 50000 U
- 100000 U
- 200000 U
- 500000 U
- 1 Million U
- Other
- By Application:
- Hospital
- Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Recombinant Human Interleukin 2 Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Recombinant human interleukin 2 (rhIL-2) is a protein that helps the body fight cancer. It is given as an injection into a vein.
Some of the key players operating in the recombinant human interleukin 2 injection market are Jiangsu Jinsili Pharmaceutical, 3SBio, Beijing SL Pharm, Shanghai Huaxin Biology Gaojishu, Beijing Four Rings Biopharmaceutical, Beijing Yuance Pharmaceutical, Shandong Quangang Pharmaceutical, Jiangsu Jinsili Pharmaceutical.
The recombinant human interleukin 2 injection market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Recombinant Human Interleukin 2 Injection Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Recombinant Human Interleukin 2 Injection Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Recombinant Human Interleukin 2 Injection Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Recombinant Human Interleukin 2 Injection Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Recombinant Human Interleukin 2 Injection Market Size & Forecast, 2018-2028
4.5.1 Recombinant Human Interleukin 2 Injection Market Size and Y-o-Y Growth
4.5.2 Recombinant Human Interleukin 2 Injection Market Absolute $ Opportunity
Chapter 5 Global Recombinant Human Interleukin 2 Injection Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Recombinant Human Interleukin 2 Injection Market Size Forecast by Type
5.2.1 50000 U
5.2.2 100000 U
5.2.3 200000 U
5.2.4 500000 U
5.2.5 1 Million U
5.2.6 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Recombinant Human Interleukin 2 Injection Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Recombinant Human Interleukin 2 Injection Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Recombinant Human Interleukin 2 Injection Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Recombinant Human Interleukin 2 Injection Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Recombinant Human Interleukin 2 Injection Analysis and Forecast
9.1 Introduction
9.2 North America Recombinant Human Interleukin 2 Injection Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Recombinant Human Interleukin 2 Injection Market Size Forecast by Type
9.6.1 50000 U
9.6.2 100000 U
9.6.3 200000 U
9.6.4 500000 U
9.6.5 1 Million U
9.6.6 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Recombinant Human Interleukin 2 Injection Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Recombinant Human Interleukin 2 Injection Analysis and Forecast
10.1 Introduction
10.2 Europe Recombinant Human Interleukin 2 Injection Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Recombinant Human Interleukin 2 Injection Market Size Forecast by Type
10.6.1 50000 U
10.6.2 100000 U
10.6.3 200000 U
10.6.4 500000 U
10.6.5 1 Million U
10.6.6 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Recombinant Human Interleukin 2 Injection Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Recombinant Human Interleukin 2 Injection Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Recombinant Human Interleukin 2 Injection Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Recombinant Human Interleukin 2 Injection Market Size Forecast by Type
11.6.1 50000 U
11.6.2 100000 U
11.6.3 200000 U
11.6.4 500000 U
11.6.5 1 Million U
11.6.6 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Recombinant Human Interleukin 2 Injection Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Recombinant Human Interleukin 2 Injection Analysis and Forecast
12.1 Introduction
12.2 Latin America Recombinant Human Interleukin 2 Injection Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Recombinant Human Interleukin 2 Injection Market Size Forecast by Type
12.6.1 50000 U
12.6.2 100000 U
12.6.3 200000 U
12.6.4 500000 U
12.6.5 1 Million U
12.6.6 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Recombinant Human Interleukin 2 Injection Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Recombinant Human Interleukin 2 Injection Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Recombinant Human Interleukin 2 Injection Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Recombinant Human Interleukin 2 Injection Market Size Forecast by Type
13.6.1 50000 U
13.6.2 100000 U
13.6.3 200000 U
13.6.4 500000 U
13.6.5 1 Million U
13.6.6 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Recombinant Human Interleukin 2 Injection Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Recombinant Human Interleukin 2 Injection Market: Competitive Dashboard
14.2 Global Recombinant Human Interleukin 2 Injection Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Jiangsu Jinsili Pharmaceutical
14.3.2 3SBio
14.3.3 Beijing SL Pharm
14.3.4 Shanghai Huaxin Biology Gaojishu
14.3.5 Beijing Four Rings Biopharmaceutical
14.3.6 Beijing Yuance Pharmaceutical
14.3.7 Shandong Quangang Pharmaceutical
14.3.8 Jiangsu Jinsili Pharmaceutical
